Page 3 - Hnis

Over 75% HNIs want to buy over Rs 5 cr properties in 2 years: Survey

Around 75 per cent wealthy people will look to buy luxury properties, worth more than Rs 5 crore, over the next two years in big cities as well as holiday destinations, according to a survey. India Sotheby's International Realty, one of the leading brokerage firms in luxury real estate space, has conducted a survey of over 200 HNIs (High Net worth Individuals) and ultra-HNIs to gauge the mood of the luxury real estate buyers across India's top 8 cities/regions -- Delhi-NCR, Mumbai, Kolkata, Bengaluru, Hyderabad, Pune, Chennai, and Goa. "An overwhelming 76 per cent respondents said they would look to buy real estate in the coming two years," according to the report 'Luxury Housing Outlook-2022'. This signals a very strong turnaround in sentiments for real estate amongst the wealthy in India, it added. Out of the 76 per cent wanting to buy real estate, 89 per cent would prefer luxury homes (city apartments, city bungalows and holiday homes), while the rest 11 per cent prefer premium

International funds can provide protection against rupee depreciation

When remitting money abroad, go with the player that offers the most attractive exchange rate

Sebi proposes sweeping changes to HNI allotment process for IPOs

Also suggests changes to price discovery norms

Losing steam: IPO bets of wealthy investors turn sour in August

Overall, HNIs have profited in 16 out of 27 IPOs in 2021

KFC operator makes strong market debut; four stocks list on the same day

The four IPOs cumulatively generated bids worth Rs 1.7 trillion and attracted over 10 million retail applications

Rolex Rings jumps 30% on debut to close with Rs 267 gain; HNIs incur losses

HNI portion was subscribed 360x; break-even after factoring in the interest cost for wealthy investors worked out between Rs 1,400-1,500 a share versus closing price of Rs 1,167

HNIs incur losses as Glenmark Life Sciences ends flat on listing day

Market observers said HNIs had placed leveraged bets, and lost big as their break even cost was more than Rs 850 per share

Ujjivan may move resolution again to appoint Samit Ghosh MD & CEO

The firm is reaching out to shareholders again in this issue after they voted against Ghosh earlier

Easy Trip gains 10% on debut; analysts say HNIs made losses on IPO

The listing was muted compared to the oversubscription seen during the IPO

Public sector IPOs warm up to anchor investors a decade down the line

Centre for the first time exercises provision for IRFC issue

Street signs: Mrs Bector's GMP, Gland Pharma on FPI red-flag list and more

If grey market activity is to be believed, despite the high acquisition price, HNIs will make money.

Investment in house on discounts ideal for high net worth individual now

Demand has been lacklustre and prices have not moved up much in the past few years

Why retail, HNI investors may be regretting giving Gland Pharma IPO a miss

Gland Pharma, promoted by China's Fosun, has extended its gains, is up 40 per cent since its listing

HNIs tap new ways to protect debt investments amid record fund raising

Many are looking at covenants previously available only to institutions, such as first loss default guarantees. Covered bonds also gaining in popularity

Hong Kong-based PAG picks 51% stake in Edelweiss Wealth for Rs 2,200 cr

PAG has been an active investor in the Asian region and most of its deals involve taking control as is the case with the latest Edelweiss investment

Equity schemes clock largest outflows in 7 years as redemptions pick up

Gold ETFs drew largest monthly flows in five months amid risk-aversion

Street signs: Nifty in bullish territory, HNIs look to break even, and more

Rossari Biotech will make its stock market debut this week following a hugely successful IPO, which saw 80 times subscription

BS READS: Zerodha's run to top is made of more than just 'free' brokerage

The company's tight-aggressive business model has done well so far, but with other players, both traditional and new, smelling an opportunity, there could be a very fascinating game ahead

HNIs turn to low-return products; tax-free bonds, FDs preferred choices

Tax-free bonds, FDs, RBI 7.75% bonds, gilt funds preferred choices

HNIs steer clear of illiquid investments after Covid-19 outbreak

Market-linked debentures and credit risk funds - two products to have grown popular in the past two years - have fallen out of favour since the outbreak